Co- and Multi-Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review
IF 7.7
1区 医学
Q1 CLINICAL NEUROLOGY
Michele Matarazzo MD, Per Borghammer MD, PhD, DMSc, Inas Elsayed PhD, Jennifer G. Goldman MD, MS, Yue Huang MD, PhD, Katja Lohmann PhD, Per Svenningsson MD, PhD, Lorraine V. Kalia MD, PhD, Daniela Berg MD, Jeffrey H. Kordower PhD, the MDS Scientific Issues Committee
下载PDF
{"title":"Co- and Multi-Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review","authors":"Michele Matarazzo MD, Per Borghammer MD, PhD, DMSc, Inas Elsayed PhD, Jennifer G. Goldman MD, MS, Yue Huang MD, PhD, Katja Lohmann PhD, Per Svenningsson MD, PhD, Lorraine V. Kalia MD, PhD, Daniela Berg MD, Jeffrey H. Kordower PhD, the MDS Scientific Issues Committee","doi":"10.1002/mds.70324","DOIUrl":null,"url":null,"abstract":"<p>Parkinson's disease (PD) has been historically defined as a disease of striatal dopamine deficiency secondary to degeneration of dopaminergic neurons in the substantia nigra pars compacta, related to the presence of Lewy bodies and Lewy neurites. Since the discovery of pathogenic variants in the gene encoding α-synuclein, as well as the finding that α-synuclein is a major constituent of Lewy pathology, PD is considered as a prototypical synucleinopathy. However, neuropathological studies consistently show that most people with PD display copathologies, many of which are linked to specific clinical features and outcomes. In this review, we summarize the spectrum and frequency of these co- and multi-pathologies in idiopathic and genetic PD and their impact on disease initiation and progression. Additionally, we also discuss how this multi-pathological landscape may impact biomarker research and the implementation of emerging disease-modifying therapies. © 2026 The Author(s). <i>Movement Disorders</i> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"41 8","pages":"1979-1992"},"PeriodicalIF":7.7000,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.70324","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/mds.70324","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
引用
批量引用
Abstract
Parkinson's disease (PD) has been historically defined as a disease of striatal dopamine deficiency secondary to degeneration of dopaminergic neurons in the substantia nigra pars compacta, related to the presence of Lewy bodies and Lewy neurites. Since the discovery of pathogenic variants in the gene encoding α-synuclein, as well as the finding that α-synuclein is a major constituent of Lewy pathology, PD is considered as a prototypical synucleinopathy. However, neuropathological studies consistently show that most people with PD display copathologies, many of which are linked to specific clinical features and outcomes. In this review, we summarize the spectrum and frequency of these co- and multi-pathologies in idiopathic and genetic PD and their impact on disease initiation and progression. Additionally, we also discuss how this multi-pathological landscape may impact biomarker research and the implementation of emerging disease-modifying therapies. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
帕金森氏病的共同和多重病理:国际帕金森氏病和运动障碍学会科学问题委员会评论。
帕金森病(PD)历来被定义为一种纹状体多巴胺缺乏症,继发于黑质致密部多巴胺能神经元变性,与路易小体和路易神经突的存在有关。由于α-synuclein编码基因的致病变异的发现,以及α-synuclein是Lewy病理的主要组成部分,PD被认为是一种典型的synuclein病。然而,神经病理学研究一致表明,大多数PD患者表现出病理,其中许多与特定的临床特征和结果有关。在这篇综述中,我们总结了特发性和遗传性PD的这些共同和多重病理的频谱和频率,以及它们对疾病发生和进展的影响。此外,我们还讨论了这种多病理景观如何影响生物标志物研究和新兴疾病修饰疗法的实施。©2026作者。Wiley期刊有限责任公司代表国际帕金森和运动障碍学会出版的《运动障碍》。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
来源期刊
期刊介绍:
Movement Disorders publishes a variety of content types including Reviews, Viewpoints, Full Length Articles, Historical Reports, Brief Reports, and Letters. The journal considers original manuscripts on topics related to the diagnosis, therapeutics, pharmacology, biochemistry, physiology, etiology, genetics, and epidemiology of movement disorders. Appropriate topics include Parkinsonism, Chorea, Tremors, Dystonia, Myoclonus, Tics, Tardive Dyskinesia, Spasticity, and Ataxia.